Understanding Biologic Therapies for Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a chronic skin condition characterized by painful lumps, abscesses, and scarring, often making it difficult to manage. Conventional treatments sometimes fall short, leading to the exploration of biologics as a promising alternative for patients with moderate to severe HS. Biologics are medications derived from living organisms that target specific components of the immune system. This blog delves into several biologics that have shown success in treating HS, highlighting their effectiveness and the key studies that support their use. (HiSCR). The Hidradenitis Suppurativa Clinical Response.

Adalimumab (Humira):

Adalimumab is a TNF-α inhibitor initially developed for rheumatoid arthritis and later approved for other inflammatory conditions, including Crohn’s disease, psoriasis, and ulcerative colitis. It works by blocking TNF-α, a cytokine involved in systemic inflammation.

Key Studies: The efficacy of Adalimumab in HS was established through the PIONEER I & II trials. In the PIONEER I trial, 307 patients were randomized to receive Adalimumab or a placebo. The primary endpoint was the percentage of patients achieving HiSCR (at least a 50% reduction in abscesses and inflammatory nodules with no increase in abscesses or draining fistulas) at week 12. The results showed that 41.8% of patients treated with Adalimumab achieved HiSCR at week 12, compared to 26.0% in the placebo group. The PIONEER II trial included 326 patients and extended the assessment to week 36, with 58.9% of patients treated with Adalimumab achieving HiSCR at week 12 compared to 27.6% in the placebo group.
Conclusion: Adalimumab demonstrated significant efficacy in reducing the signs and symptoms of HS compared to placebo, leading to its FDA approval for HS in 2015. Its success rates range from 42% to 59% in achieving HiSCR, making it a cornerstone in HS treatment.
2. Infliximab (Remicade):
Infliximab is a monoclonal antibody targeting TNF-α, primarily developed for the treatment of Crohn’s disease and rheumatoid arthritis. It was later approved for other conditions like ankylosing spondylitis, psoriatic arthritis, and ulcerative colitis.

Key Studies: In an open-label study conducted by Grant et al. in 2010, seven patients with severe HS who had not responded to conventional treatments were treated with Infliximab (5 mg/kg) at weeks 0, 2, 6, and then every 8 weeks. The results were promising, with all seven patients showing significant improvement in their HS symptoms, and some achieving partial or complete remission. Additionally, a systematic review by Leslie et al. in 2021 analyzed seven studies with a total of 122 patients. Approximately 82% of patients treated with Infliximab showed significant improvement in HS symptoms, though the duration of response varied among patients.

Conclusion: Infliximab has proven to be effective for many patients with HS, particularly in severe cases where other treatments have failed. Its success rate of approximately 82% in clinical response underscores its potential as a valuable treatment option, though it is primarily used off-label.

Ustekinumab (Stelara):

Ustekinumab is an interleukin-12 (IL-12) and interleukin-23 (IL-23) inhibitor, originally developed for the treatment of moderate to severe plaque psoriasis. It was later approved for psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Key Studies: Ustekinumab has shown potential in treating refractory HS. In a case series conducted by Gonzalez-Lopez et al. in 2012, three patients with severe HS were treated with Ustekinumab (45 mg or 90 mg depending on body weight) at weeks 0, 4, and every 12 weeks thereafter. All three patients showed significant clinical improvement, with reductions in inflammatory nodules and abscesses. A retrospective study by Kumar et al. in 2016 included eight patients treated with Ustekinumab. The study found that 75% of patients achieved partial or complete remission of their HS symptoms, further supporting its potential role in treating HS.
Conclusion: Ustekinumab shows promise in treating refractory HS, with success rates ranging from 75% to 100% in small studies. However, more extensive research is recommended to fully establish its efficacy in a broader patient population.

Secukinumab (Cosentyx):

Secukinumab is an interleukin-17A (IL-17A) inhibitor, initially developed and approved for the treatment of moderate to severe plaque psoriasis. It was later approved for psoriatic arthritis and ankylosing spondylitis.

Key Studies: The ongoing SAHARA study, a Phase 3 trial, is investigating the efficacy of Secukinumab in HS patients. Preliminary results suggest a reduction in inflammatory nodules, though full results are pending. In an open-label study by Hofmann et al. in 2018, nine patients with severe HS were treated with Secukinumab, and 67% of patients showed clinical improvement in HS symptoms.
Conclusion: While Secukinumab has shown potential in treating HS, particularly in reducing inflammatory nodules, further research is necessary to confirm its efficacy. The ongoing SAHARA study may provide more definitive answers in the future.

Anakinra (Kineret):
Anakinra is an interleukin-1 (IL-1) receptor antagonist, originally developed for the treatment of rheumatoid arthritis. It is also used for certain autoinflammatory syndromes, such as neonatal-onset multisystem inflammatory disease (NOMID).

Key Studies: Anakinra has shown effectiveness in reducing inflammation and pain in HS patients. In a randomized, double-blind, placebo-controlled study by Tzanetakou et al. in 2016, 20 patients with moderate to severe HS were randomized to receive either Anakinra or placebo. The results showed that 78.9% of patients treated with Anakinra showed a significant reduction in disease activity, compared to 30% in the placebo group. Additionally, a pilot study by van der Zee et al. in 2010 involved six patients with severe HS treated with Anakinra (100 mg daily). All six patients achieved partial or complete remission, with significant reductions in pain and inflammatory nodules.

Conclusion: Anakinra is a promising treatment for HS, particularly for those with severe or refractory disease. Its success rates range from 79% to 100% in small studies, making it a valuable option for patients who have not responded to other therapies.

Anakinra (Kineret):
Anakinra is an interleukin-1 (IL-1) receptor antagonist, originally developed for the treatment of rheumatoid arthritis. It is also used for certain autoinflammatory syndromes, such as neonatal-onset multisystem inflammatory disease (NOMID).

Key Studies: Anakinra has shown effectiveness in reducing inflammation and pain in HS patients. In a randomized, double-blind, placebo-controlled study by Tzanetakou et al. in 2016, 20 patients with moderate to severe HS were randomized to receive either Anakinra or placebo. The results showed that 78.9% of patients treated with Anakinra showed a significant reduction in disease activity, compared to 30% in the placebo group. Additionally, a pilot study by van der Zee et al. in 2010 involved six patients with severe HS treated with Anakinra (100 mg daily). All six patients achieved partial or complete remission, with significant reductions in pain and inflammatory nodules.
Conlusion: Anakinra is a promising treatment for HS, particularly for those with severe or refractory disease. Its success rates range from 79% to 100% in small studies, making it a valuable option for patients who have not responded to other therapies.

Biologic therapies such as Adalimumab, Infliximab, Ustekinumab, Secukinumab, and Anakinra represent a significant advancement in the treatment of Hidradenitis Suppurativa. These biologics have shown varying degrees of success in clinical trials, offering hope to patients who struggle with this challenging condition. While these treatments are promising, ongoing research is essential to fully establish their efficacy and safety in broader patient populations. As the understanding of HS continues to evolve, biologic therapies may become an even more integral part of managing this complex condition.

Understanding Biologic Therapies for Hidradenitis Suppurativa

Adalimumab (Humira):

Ustekinumab (Stelara):

Secukinumab (Cosentyx):

Join our HS Healers Facebook Group!

Useful Link

About

Products

Contact

My Account

Resources

Blog

FAQ

Refund and Returns Policy

Get in Touch

© 2024, Amazing Ointments, All Rights Reserved